Currently, there are two types of hormonal treatments available for ER responsive breast cancer, which use either an anti-ER drug (e.g., tamoxifen) [9] or an aromatase inhibitor (e.g., letrozole) [10]. The gene discussed is CYP19A1; the disease is breast cancer.